Literature DB >> 12078761

Prognostic significance of neuroendocrine differentiation in adenocarcinoma of the lung.

Kenzo Hiroshima1, Akira Iyoda, Kiyoshi Shibuya, Tetsuya Toyozaki, Yukiko Haga, Takehiko Fujisawa, Hidemi Ohwada.   

Abstract

BACKGROUND: The relative incidence of adenocarcinoma of the lung is increasing and some patients with lung carcinoma, detected at an early stage, still develop recurrent disease despite complete resection of the tumor. Recently, neuroendocrine differentiation in large cell carcinoma of the lung has been reported to be of prognostic significance. Therefore, we have evaluated the prognostic significance of neuroendocrine differentiation in adenocarcinoma of the lung.
METHODS: A total of 90 resected specimens of adenocarcinoma of the lung measuring 3 cm or less (T1 N0 M0 or T2 N0 M0) were reviewed histologically and immunohistochemical staining was performed to determine the degree of neuroendocrine differentiation.
RESULTS: Seven adenocarcinomas exhibited neuroendocrine differentiation in 10% or more of tumor cells. The disease-free survival rate for these patients was significantly lower than that of patients with tumors exhibiting neuroendocrine differentiation in less than 10% of tumor cells or with absent neuroendocrine differentiation (p < 0.0005). Other conventional pathologic factors such as vascular invasion (p < 0.0005), lymphatic invasion (p < 0.05), and pleural involvement (p < 0.05) were also of prognostic significance. In multivariate analysis, the presence of 10% or more neuroendocrine marker-positive tumor cells, vascular invasion, and lymphatic invasion were found to be significantly adverse prognostic factors (p = 0.0162, p = 0.0111, and p = 0.0173, respectively).
CONCLUSIONS: Neuroendocrine differentiation of tumor cells is a prognostic factor in lung adenocarcinoma. It is suggested that the identification of neuroendocrine differentiation as well as vascular invasion by tumor in small peripheral adenocarcinoma of the lung may predict the prognosis of these patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12078761     DOI: 10.1016/s0003-4975(02)03504-x

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  8 in total

1.  Clinical relevance of neuroendocrine differentiation in non-small cell lung cancer assessed by immunohistochemistry: a retrospective study on 405 surgically resected cases.

Authors:  William Sterlacci; Michael Fiegl; Wolfgang Hilbe; Jutta Auberger; Gregor Mikuz; Alexandar Tzankov
Journal:  Virchows Arch       Date:  2009-08-04       Impact factor: 4.064

2.  Plasma neuron-specific enolase level as a prognostic marker in patients with non-small cell lung cancer receiving gefitinib.

Authors:  Minehiko Inomata; Ryuji Hayashi; Azusa Yamamoto; Kotaro Tokui; Chihiro Taka; Seisuke Okazawa; Kenta Kambara; Kensuke Suzuki; Tomomi Ichikawa; Toru Yamada; Toshiro Miwa; Tatsuhiko Kashii; Shoko Matsui; Kazuyuki Tobe; Johji Imura
Journal:  Mol Clin Oncol       Date:  2015-05-14

3.  Positive expression of pro-opiomelanocortin (POMC) is a novel independent poor prognostic marker in surgically resected non-small cell lung cancer.

Authors:  Ligang Hao; Xiaoliang Zhao; Bin Zhang; Chenguang Li; Changli Wang
Journal:  Tumour Biol       Date:  2014-11-07

4.  Neuroendocrine differentiation in gastric adenocarcinomas; correlation with tumor stage and expression of VEGF and p53.

Authors:  Funda Eren; Ciğdem Celikel; Bahadir Güllüoğlu
Journal:  Pathol Oncol Res       Date:  2004-03-18       Impact factor: 3.201

5.  NEUROENDOCRINE TUMORS OF THE LUNG WITH SURGICAL RESECTION AND LYMPH NODE DISSECTION IN A TERTIARY THORACIC SURGERY CENTER.

Authors:  N Motas; C Motas; M Davidescu; D Achim; O Rus; E Jianu; T Horvat
Journal:  Acta Endocrinol (Buchar)       Date:  2018 Apr-Jun       Impact factor: 0.877

Review 6.  Multiple faces of pulmonary large cell neuroendocrine carcinoma: update with a focus on practical approach to diagnosis.

Authors:  Marina K Baine; Natasha Rekhtman
Journal:  Transl Lung Cancer Res       Date:  2020-06

7.  Alterations in gene expression of proprotein convertases in human lung cancer have a limited number of scenarios.

Authors:  Ilya V Demidyuk; Andrey V Shubin; Eugene V Gasanov; Alexander M Kurinov; Vladimir V Demkin; Tatyana V Vinogradova; Marina V Zinovyeva; Alexander V Sass; Irina B Zborovskaya; Sergey V Kostrov
Journal:  PLoS One       Date:  2013-02-07       Impact factor: 3.240

8.  Pirfenidone suppresses polarization to M2 phenotype macrophages and the fibrogenic activity of rat lung fibroblasts.

Authors:  Michihito Toda; Shinjiro Mizuguchi; Yukiko Minamiyama; Hiroko Yamamoto-Oka; Takanori Aota; Shoji Kubo; Noritoshi Nishiyama; Toshihiko Shibata; Shigekazu Takemura
Journal:  J Clin Biochem Nutr       Date:  2018-04-11       Impact factor: 3.114

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.